LGALS9 and neoplasm: Although anti-PD1 monoclonal antibodies had no effect against miR-93-OE-derived xenografts, tumor shrinkage was observed when combining anti-GAL-9 and anti-PD1 treatments, providing evidence for promising GAL-9 targeting in combined strategies for the treatment of LPC-like HCC subtypes [113].